Abstract

PurposeProviral integration site for Moloney murine leukemia virus (PIMs) are proto-oncogenes encoding serine/threonine kinases that phosphorylate a variety of substrates involved in the regulation of cellular processes. Elevated expression of PIM-1 has been associated with poor prognosis in several types of cancer. There are no studies that have analyzed the response to radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC) according to the expression of PIM-1. The aim of our study was to analyze the relationship between the transcriptional expression of PIM-1 and local response to radiotherapy in HNSCC patients.MethodsWe determined the transcriptional expression of PIM-1 in 135 HNSCC patients treated with radiotherapy, including patients treated with chemoradiotherapy (n = 65) and bioradiotherapy (n = 15).ResultsDuring the follow-up, 48 patients (35.6%) had a local recurrence of the tumor. Patients with local recurrence had a higher level of PIM-1 expression than those who achieved local control of the disease (P = 0.017). Five-year local recurrence-free survival for patients with a high expression of PIM-1 (n = 43) was 44.6% (95% CI 29.2–60.0%), and for patients with low expression (n = 92) it was 71.9% (95% CI 62.5–81.3%) (P = 0.007). According to the results of multivariate analysis, patients with a high PIM-1 expression had a 2.2-fold increased risk of local recurrence (95% CI 1.22–4.10, P = 0.009).ConclusionPatients with elevated transcriptional expression levels of PIM-1 had a significantly higher risk of local recurrence after radiotherapy.

Highlights

  • Radiotherapy is one of the therapeutic options for patients with head and neck squamous cell carcinoma (HNSCC)

  • Elevated expression of PIM-1 has been associated with poor prognosis in patients with leukemia [2] or lymphoma [3], as well as in patients with squamous cell carcinomas located in the esophagus [4] or the lung [5], or adenocarcinomas located in the breast [6], lung [5], pancreas [7], colon [8], stomach [9] or prostate [10]

  • The transcriptional expression of PIM-1 was significantly related to the local control of the tumor in patients with HNSCC treated with radiotherapy, chemoradiotherapy, or bioradiotherapy

Read more

Summary

Introduction

Radiotherapy is one of the therapeutic options for patients with head and neck squamous cell carcinoma (HNSCC). A variable percentage of patients, depending on the location and extension of the tumor, have a local recurrence. The availability of biomarkers with the capacity to discriminate tumor radiosensitivity would make it possible to offer radiotherapy to those patients with tumors with a greater probability of response, reducing the percentage of local recurrence and the need for salvage surgery. Elevated expression of PIM-1 has been associated with poor prognosis in patients with leukemia [2] or lymphoma [3], as well as in patients with squamous cell carcinomas located in the esophagus [4] or the lung [5], or adenocarcinomas located in the breast [6], lung [5], pancreas [7], colon [8], stomach [9] or prostate [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call